AstraZeneca to pay an additional $68.5 million to settle US lawsuits over malpractice practices marketing for the antipsychotic Seroquel (quetiapine). The allegations relate to alleged activities aimed at promoting the use of the drug not approved by the regulatory authorities and inadequate information on possible side effects. The settlement, with 37 states and the District of Columbia, is separate from the one signed in 2010 that resulted in a $520 million payment from the company to the US government to settle similar litigation.
(The Wall Street Journal online – 10/03/2011 , International Herald Tribune Pag.19 – 11/03/2011) 
